Back to Stocks

TCNNF

Trulieve Cannabis Corp.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Trulieve Cannabis Corp. has reached a pivotal financial turning point, transitioning from a high-tax burden operator to a federally aligned powerhouse.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative surrounding federal rescheduling, Trulieve's core retail engine is showing signs of fatigue.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TCNNF filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in the midst of a high-stakes transition. The immediate financial impact of the DOJ's rescheduling of medical cannabis is undeniably positive, providing a massive reprieve from the tax burdens that have historically plagued the industry. This has allowed Trulieve to pivot from deep losses to a positive net income, while maintaining a very strong liquidity position. However, the underlying operational data suggests a challenging environment. The decline in retail revenue and the contraction of gross margins indicate that the company is fighting a difficult battle against price erosion. Investors must weigh the massive potential of federal normalization against the reality of a deteriorating retail market and a lingering cloud of federal illegality for adult-use products. The ultimate trajectory of the stock will likely depend on whether the tax savings can outpace the operational headwinds of a maturing, more competitive market.

Selected Quarter

Core Takeaway

The elimination of the 280E tax burden for medical operations has shifted Trulieve from net losses to profitability, though core retail growth is stalling.

Investor Lens

The trade-off is between a massive regulatory tailwind (tax/legality) and a deteriorating operational headwind (retail price compression).

Watch Next

The progress of the adult-use rescheduling process and the outcome of the IRS appeals regarding prior-year penalties.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.49Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%
bullishMay 7

Net income swung from a $32.9M loss to a $2.4M profit due to tax normalization.

earnings beat
90%
bearishMay 7

Gross margin declined from 61.5% to 59.3% due to retail price compression.

margin compression
60%
bullishMay 7

Secured $60.7 million through a new debt issuance to bolster liquidity.

capital raise
70%
bullishMay 7

Medical cannabis rescheduled to Schedule III, removing 280E tax burdens for 2026.

regulatory action
95%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company in the midst of a high-stakes transition. The immediate financial impact of the DOJ's rescheduling of medical cannabis is undeniably positive, providing a massive reprieve from the tax burdens that have historically plagued the industry. This has allowed Trulieve to pivot from deep losses to a positive net income, while maintaining a very strong liquidity position. However, the underlying operational data suggests a challenging environment. The decline in retail revenue and the contraction of gross margins indicate that the company is fighting a difficult battle against price erosion. Investors must weigh the massive potential of federal normalization against the reality of a deteriorating retail market and a lingering cloud of federal illegality for adult-use products. The ultimate trajectory of the stock will likely depend on whether the tax savings can outpace the operational headwinds of a maturing, more competitive market.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.